Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02350764
Title Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Memorial Sloan Kettering Cancer Center
Indications

lung non-small cell carcinoma

Therapies

Ipilimumab + Nivolumab

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST